Lexeo Therapeutics (NASDAQ:LXEO) Insider Sells $98,592.52 in Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) insider Narinder Pal Bhalla sold 22,306 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total value of $98,592.52. Following the completion of the sale, the insider owned 82,194 shares of the company’s stock, valued at approximately $363,297.48. This trade represents a 21.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Lexeo Therapeutics Stock Performance

Shares of NASDAQ LXEO opened at $4.69 on Friday. Lexeo Therapeutics, Inc. has a fifty-two week low of $3.60 and a fifty-two week high of $10.99. The company has a market cap of $368.26 million, a PE ratio of -3.23 and a beta of 1.42. The business has a 50-day simple moving average of $5.06 and a two-hundred day simple moving average of $6.58.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04. On average, sell-side analysts predict that Lexeo Therapeutics, Inc. will post -1.21 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lexeo Therapeutics

Hedge funds have recently bought and sold shares of the stock. Allworth Financial LP grew its stake in shares of Lexeo Therapeutics by 1,002.9% during the 4th quarter. Allworth Financial LP now owns 3,386 shares of the company’s stock worth $34,000 after purchasing an additional 3,079 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Lexeo Therapeutics by 69.9% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company’s stock valued at $35,000 after purchasing an additional 1,459 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of Lexeo Therapeutics in the 4th quarter valued at $37,000. California State Teachers Retirement System lifted its stake in shares of Lexeo Therapeutics by 123.7% in the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company’s stock valued at $39,000 after purchasing an additional 2,148 shares during the period. Finally, Russell Investments Group Ltd. boosted its holdings in Lexeo Therapeutics by 160.2% during the fourth quarter. Russell Investments Group Ltd. now owns 5,872 shares of the company’s stock worth $58,000 after buying an additional 3,615 shares in the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Wall Street Analysts Forecast Growth

LXEO has been the subject of a number of research analyst reports. Weiss Ratings cut shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, June 25th. Wall Street Zen raised Lexeo Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Chardan Capital restated a “buy” rating and issued a $17.00 target price on shares of Lexeo Therapeutics in a research note on Monday, May 11th. Finally, JPMorgan Chase & Co. lowered their price target on Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, June 25th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $18.75.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.